Navigation Links
Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
Date:11/29/2007

Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cystic fibrosis. This new agreement between CFFT and Galapagos BioFocus DPI service division is worth up to 5.5 million euros ($8.1 million U.S. dollars) for Galapagos.

The collaboration will combine two key strengths of BioFocus DPI expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the collaboration aims to identify small molecules derived from natural sources that improve the function of a defective protein found in people who have cystic fibrosis. The protein is called CFTR - cystic fibrosis transmembrane conductance regulator. To advance the search for a cure for cystic fibrosis, CFFT funds promising scientific research in the pharmaceutical and biotechnology industry and academia worldwide.

Under the terms of the agreement, Galapagos stands to receive up to 1.6 million ($2.4 million) in upfront and research fees over the next two years, and up to 3.8 million ($5.7 million) in success-based milestone payments, should certain clinical development criteria be met.

This drug discovery collaboration is in addition to an ongoing target discovery program established between CFFT and BioFocus DPI in April 2005.

We are excited to take advantage of the innovative drug discovery approach developed by BioFocus DPI and the companys extensive expertise in natural compounds, said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. By exploring compounds derived from natural sources, our goal is to increase the number and diversity of drug candidates in development to treat cystic fibrosis.

The CFFT drug discovery collaboration is a prime example of the kind of innovation we aimed to achieve through our acquisition strategy, said Onno van de Stolpe, CEO of Galapagos. We have seen a growing interest in natural product based drug discovery since acquiring these capabilities last year. By combining this expertise with our know-how in cell-based screening, we are confident that we will contribute to the advancement of CFFTs drug discovery program in novel ways.


'/>"/>

Contact: Lily Mccutchan
lmccutchan@cff.org
301-841-2674
Cystic Fibrosis Foundation
Source:Eurekalert

Related biology news :

1. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
2. Balzan Foundation announces 2007 winners
3. Keck Foundation funds study of biological interactions with nanomaterials
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
6. Simons Foundation awards Emory scientists $3M for autism gene research
7. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
8. Life-saving clean water project secures $13M from Bill & Melinda Gates Foundation
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. LaserCard Corporation Announces Expansion of Middle East Project
11. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
Breaking Biology Technology: